View Older Stories
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $82 at Bernstein SocGen Group
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $120 at Evercore ISI
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
-
BioMarin shares VOXZOGO data showing bone health benefits in children
-
Morgan Stanley Resumes BioMarin Pharmaceutical Inc. (BMRN) at Overweight
-
BioMarin appoints Ian Clark as board chair, Richard Meier to retire
-
Wolfe Research Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN): 'we'd be buyer on weakness'
-
Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign"
-
BioMarin reports early VOXZOGO treatment benefits for achondroplasia
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $85 at BofA Securities
-
Leerink on BioMarin Pharma (BMRN): 'We continue to hold a more cautious view on the outlook for Voxzogo'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays
-
Truist Securities Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets
-
BioMarin Pharmaceutical (BMRN) Reiterated at Overweight by Cantor Fitzgerald After Webinar
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $94 at Bernstein
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $55 at H.C. Wainwright
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $68 at Stifel
-
BioMarin Pharma (BMRN) Misses Q4 EPS by 31c; offers guidance
-
Baird on BioMarin Pharmaceutical Inc. (BMRN): 'Incrementally negative on competitor data'
-
BioMarin (BMRN), Ascendis (ASND) Trade Lower Following Competitor Data
-
Canaccord Genuity Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Buy
-
BioMarin expects $3.2 billion in 2025 revenue, ROCTAVIAN write-down
-
BioMarin names Arpit Davé as chief digital and information officer
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $100 at Truist Securities
-
BioMarin Pharma (BMRN) discontinues development of BMN 349
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $60 at H.C. Wainwright
-
Leerink Partners Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Market Perform
-
Stifel Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Hold, 'Stock Might Even Be Too Cheap, But It's Getting Harder to See the Path'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Bernstein Amid 'Tough NT Setup'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered at Truist; 'Competitive Pressures Mounting'
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $66 at RBC Capital
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $55 at H.C. Wainwright
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $73 at Stifel
-
Wolfe on BioMarin Pharmaceutical Inc. (BMRN): 'Divesting Roctavian Is A Rock Solid Move'
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 20c
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
Cantor Fitzgerald Cuts BioMarin (BMRN) PT to $80 Ahead of 3Q Earnings
-
H.C. Wainwright Starts BioMarin Pharmaceutical Inc. (BMRN) at Neutral
-
Why public perception matters so much for biotech valuations
-
Oppenheimer Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $95 at Bernstein SocGen Group
-
Stifel Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Cantor Fitzgerald Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Bernstein Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
TD Cowen Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at UBS
-
After-hours movers: Palantir, Hims & Hers, Vertex Pharma and more
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance

